get a key
steadybase-$ company CLDI
account_id none on file
legal_name Calidi Biotherapeutics, Inc.
ticker CLDI
cik 1855485
domain calidibio.com
entry_point_account_id none on file
name Calidi Biotherapeutics Inc.
exchange NYSE
sector Health Care
calls 0 filings 8 executives 2 family 0
why_nownone on file
callsnone on file
filings
October 10, 2022, we entered into an Office Lease Agreement (the “San Diego Lease”) that serves as our principal executive

filing / Aug 13, 2026 / receipt

headcount growth and associated costs as we expand our business operations and research and development activities; ● the costs of operating as a public company.

filing / Aug 13, 2026 / receipt

October 10, 2022, the Company entered into an Office Lease Agreement (the “San Diego Lease”) of a building containing 15,197

filing / Aug 13, 2026 / receipt

utilized to supplement our personnel, insurance costs, travel costs, facility and office-related costs not included in research and development

filing / May 14, 2026 / receipt

October 10, 2022, we entered into an Office Lease Agreement (the “San Diego Lease”) that serves as our principal executive and administrative offices and laboratory facility.

filing / May 14, 2026 / receipt

to the hiring of additional personnel and fees to outside service providers, among other expenses. We also anticipate continued expenses

filing / May 14, 2026 / receipt

headcount growth and associated costs as we expand our business operations and research and development activities; ● the costs of operating as a public company.

filing / May 14, 2026 / receipt

October 10, 2022, the Company entered into an Office Lease Agreement (the “San Diego Lease”) of a building containing 15,197

filing / May 14, 2026 / receipt

executives
David LaPre director - receipt
George Peoples director - receipt
familynone on file
upcoming
2026-11-12 earnings call scheduled ir
changes
2024-06-26 director, appointed sec_8k
2023-12-12 director, appointed sec_8k
mcp_package_hint
steadybase-$